Roche’s developed a fixed-dose combination using two of its breast cancer treatments, Herceptin (trastuzumab) and Perjeta (pertuzumab).

The Ministry of Food and Drug Safety approved Roche Korea’s ‘Phesgo (trastuzumab/pertuzumab) on the 6th.

Trastuzumab and pertuzumab are commonly used ingredients for breast cancer. The original brand name of trastuzumab is ‘Herceptin,’ a blockbuster drug that sold ₩69.9 billion last year according to IQVIA

The original brand name of pertuzumab is ‘Perjeta.’ It sold ₩74.1 billion last year according to IQVIA.

As the combination of the two drugs is also commonly used in metastatic or early breast canc